ClinicalTrials.gg
RecruitingNCT07302971TOGETHERUpdated Feb 3, 2026

Telemedicine-supported Management for Acute Ischemic Stroke

An interventional study of Telemedicine-Supported Management in Acute Ischemic Stroke, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies in Ischemic Stroke by Capital Medical University — 20 open to participants now, 25 under way, 10 of them phase 3. Ischemic Stroke · Capital Medical University.

Planned enrollment
Largest of 39
2,400 · median 208
Started
2026
with 9 others
No phase
14 of 45
6 open now
Primary completion
2027-06
later than 16 of 24 live
Registered
37th of 45
by date

Among the 45 studies in Ischemic Stroke by Capital Medical University, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2026, is one of 14 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 37th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

20 of the 45 studies in Ischemic Stroke by Capital Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Ischemic Stroke by Capital Medical University, or all of them as a file.
02

Study summary

Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies.

This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospital Inclusion Criteria:

    1. Basic-level hospitals in China (Definition: Hospitals classified as secondary-level (Grade II) or below under China's Hospital Grading Management Standards, or hospitals located in counties/county-level cities).
    2. Equipped with an emergency department and neurology ward capable of admitting stroke patients.
    3. Equipped with CT and/or MRI capable of diagnosing AIS.
    4. Equipped with intravenous thrombolytic drugs for acute ischemic stroke.
  • Patient Inclusion Criteria:

    1. Age ≥ 18 years.
    2. Diagnosed with acute ischemic stroke.
    3. CT/MRI confirms absence of intracerebral hemorrhage.
    4. Onset of stroke symptoms ≤ 4.5 hours.
    5. pre-stroke mRS score ≤1.
    6. obtained from patient or their legal representative.

Exclusion criteria

Exclusion Criteria:

  • Hospital Exclusion Criteria:

    1. Admitting fewer than 10 patients with acute ischemic stroke per month.
    2. Currently participating in other clinical trials that may interfere with this trial.
  • Patient Exclusion Criteria:

    1. Presence of for intravenous thrombolysis according to AHA/ASA guidelines
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    Telemedicine-Supported Group

    Receive remote guidance from expert stroke centers for treatment of patients with intravenous thrombolysis, along with quality control for standardized workflow support, and professional training.

    Other: Telemedicine-Supported Management

  • No intervention
    Standard Treatment Group without Telemedicine-Supported Management

    Control-group patients will receive routine stroke care at their primary care hospitals, with no remote consultation, study-related quality control, or extra training. Care will follow the hospitals' usual protocols, including emergency assessment, neurological evaluation, imaging, and intravenous thrombolysis. Hospitals may continue their regular stroke-related training during the study to reflect real-world practice.

Interventions

  • OtherTelemedicine-Supported Management

    Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with mRS scores of 0-1

    Time frame: 90 days

Secondary outcomes

  1. Intravenous thrombolysis rate

    Time frame: 4.5 hours

  2. mRS score

    Ranges from 0 to 6 points, with lower scores indicating better functional outcome.

    Time frame: 90 days

  3. Door-to-(thrombolysis)needle-time

    The time calculation begins when the patient arrives at the hospital and ends upon receiving thrombolytic therapy. The theoretical range is 0 to 270 minutes.

    Time frame: 4.5 hours

  4. Rate of endovascular therapy receipt among eligible patients

    Time frame: 24 hours

Other outcomes

  1. Proportion of sICH

    The time frame is within 36 hours after thrombolysis in patients. Symptomatic intracranial hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.

    Time frame: Within 36 hours of thrombolysis

  2. Proportion of any type of ICH

    The time frame is within 36 hours of thrombolysis administration. Any type of intracerebral hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.

    Time frame: Within 36 hours of thrombolysis

  3. All-cause mortality rate

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 16 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 24, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07302971
Responsible party
Ji Xunming,MD,PhD (Professor of Neurology, Xuanwu Hospital, Capital Medical University, Capital Medical University) — Principal investigator
First posted
Dec 24, 2025
Start date
Feb 2, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

Xunming Ji
Contact
jixm@ccmu.edu.cn
01083198962
Chuanjie Wu
Contact
wuchuanjie@ccmu.edu.cn
01083199439

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion